3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
Cyclophosphamide
444
Rituximab
401
Etoposide
224
Vincristine
215
Doxorubicin
201
Filgrastim
200
Prednisone
176
Cytarabine
159
Radiotherapy
152
fludarabine phosphate
147
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
129
Melphalan
127
fludarabine
115
Busulfan
99
Dexamethasone
93
Tacrolimus
75
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
71
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
62
Cyclosporine
62
Bendamustine Hydrochloride
62
Lenalidomide
60
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts